Tinlarebant (LBS-008)

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Dosage forms and strengths

1 evidence topic · 2 sources

Investigational dosage form

“orally administered tablet” (opens the source at this quote in a new tab)